Chongqing Sintaho Pharmaceutical Co., Ltd. takes chemistry as the core, located at Chongqing International Biological City in China, jointly founded by Chongqing Taihao Pharmaceutical Co., Ltd. (established in 2004) and a US new-drug enterprise in July 2016. With 260+ employees integrated with R&D, production, regulatory affairs, and marketing, Sintaho commits itself to the global market, particularly the US, EU, and China. Sintaho specializes in chemosynthetic APIs (therapeutic areas mainly contain oncology, nervous system and metabolic diseases), with a product portfolio ranging from small molecule APIs, ADC compounds (linkers and payloads) to polypeptides, also provides CDMO services of cytotoxic and OEB4/5 grade APIs. Sintaho contributes to being the most dependable partner for global pharmaceutical companies.
Year Established: 2016
Total Assets(USD): 500,000 to 99,999,999
Total Number of Staff: 100-500
Main Competitive Advantages: International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Quality Service
Business Type: Manufacturer
R&D Capacity: OEM,ODM,Own Brand
Annual Turnover(USD) : 500,000 to 99,999,999
Main Sales Markets : North America,Central/South America,Western Europe,Eastern Europe,Australasia
Subscribe to the latest newsletter of Virtual Expo Connect
SO-PNP
PO-PNP
MIP-PNP
ER-PNP